艾立布林治疗乳腺癌术后复发的效果及预后影响因素分析  

Effect of eribulin on postoperative recurrence of breast cancer and analysis of prognostic factors

作　　者：李凯强 王新星[1] 薛兵建 孙萌 甘丽 解钧媛 裴新红[1] Li Kaiqiang;Wang Xinxing;Xue Bingjian;Sun Meng;Gan Li;Xie Junyuan;Pei Xinhong(The Second Department of Breast Surgery,The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)

机构地区：[1]郑州大学第一附属医院乳腺外二科,郑州450052

出　　处：《河南外科学杂志》2023年第3期4-7,共4页Henan Journal of Surgery

基　　金：河南省高等学校重点科研项目计划(22A320004)。

摘　　要：目的探讨艾立布林治疗乳腺癌术后复发的效果及预后影响因素。方法回顾性分析2020-07-2022-03于郑州大学第一附属医院乳腺外科行艾立布林治疗的58例乳腺癌术后复发患者的临床病理资料和不良反应。研究主要终点为客观缓解率(ORR)、中位无进展生存期(PFS),以及临床获益率(CBR)和艾立布林治疗的安全性。结果患者的ORR为27.6%(16/58),CBR为32.8%(19/58),中位PFS为3.2个月。转移部位数目、化疗线数是艾立布林疗效的独立影响因素(P<0.05);不良事件中血液学不良反应最常见,其中中性粒细胞减少率为48.3%(28/58),3~4级占13.8%(8/58)。结论艾立布林用于乳腺癌术后复发患者,疗效良好,且不良事件可控。Objective To investigate the effect of eribulin on postoperative recurrence of breast cancer and its prognostic factors.Methods The clinicopathological data and adverse reactions of 58 patients with postoperative recurrence of breast cancer who were treated with eribulin in the Breast Surgery Department of the First Affiliated Hospital of Zhengzhou University from July 2020 to March 2022 were retrospectively analyzed.The main endpoints of the study were objective response rate(ORR),median progression free survival(PFS),and clinical benefit rate(CBR),as well as the safety of eribulin treatment.Results The ORR was 27.6%(16/58),CBR was 32.8%(19/58),median PFS was 3.2 months.The number of metastatic sites and the number of chemotherapy lines were independent factors influencing the efficacy of eribulin(P<0.05).Hematology adverse reactions are the most common among adverse events,with neutropenia accounting for 48.3%(28/58)and grades 3~4 accounting for 13.8%(8/58).Conclusion The efficacy of eribulin in patients with postoperative recurrence of breast cancer is good,and adverse events are controllable.

关 键 词：艾立布林 晚期乳腺癌 化疗 不良反应 

分 类 号：R737.9[医药卫生—肿瘤]